ESPERION THERAPEUTICS INC (ESPR) Stock Price & Overview
NASDAQ:ESPR • US29664W1053
The current stock price of ESPR is 2.77 USD. Today ESPR is down by -4.81%. In the past month the price decreased by -19.01%. In the past year, price increased by 63.91%.
ESPR Key Statistics
- Market Cap
- 662.196M
- P/E
- N/A
- Fwd P/E
- 21.53
- EPS (TTM)
- -0.50
- Dividend Yield
- N/A
ESPR Stock Performance
ESPR Stock Chart
ESPR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ESPR. When comparing the yearly performance of all stocks, ESPR is one of the better performing stocks in the market, outperforming 80.16% of all stocks.
ESPR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ESPR. ESPR has a bad profitability rating. Also its financial health evaluation is rather negative.
ESPR Earnings
On November 6, 2025 ESPR reported an EPS of -0.16 and a revenue of 87.31M. The company missed EPS expectations (-183.71% surprise) and beat revenue expectations (10.02% surprise).
ESPR Forecast & Estimates
14 analysts have analysed ESPR and the average price target is 6.96 USD. This implies a price increase of 151.34% is expected in the next year compared to the current price of 2.77.
For the next year, analysts expect an EPS growth of 80.08% and a revenue growth 27.75% for ESPR
ESPR Groups
Sector & Classification
ESPR Financial Highlights
Over the last trailing twelve months ESPR reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 21.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.07% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ESPR Ownership
ESPR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 29.29 | 929.554B | ||
| JNJ | JOHNSON & JOHNSON | 20.57 | 577.341B | ||
| MRK | MERCK & CO. INC. | 21.45 | 288.088B | ||
| PFE | PFIZER INC | 8.86 | 151.297B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 17.8 | 53.866B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.81 | 26.368B | ||
| VTRS | VIATRIS INC | 5.79 | 16.73B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.74 | 11.892B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.259B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.474B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.46B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 4.217B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ESPR
Company Profile
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 304 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Company Info
ESPERION THERAPEUTICS INC
3891 Ranchero Drive, Suite 150, Suite 300
Ann Arbor MICHIGAN 48108 US
CEO: Tim M. Mayleben
Employees: 304
Phone: 17348873903
ESPERION THERAPEUTICS INC / ESPR FAQ
What does ESPERION THERAPEUTICS INC do?
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 304 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
What is the current price of ESPR stock?
The current stock price of ESPR is 2.77 USD. The price decreased by -4.81% in the last trading session.
What is the dividend status of ESPERION THERAPEUTICS INC?
ESPR does not pay a dividend.
What is the ChartMill technical and fundamental rating of ESPR stock?
ESPR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists ESPR stock?
ESPR stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for ESPERION THERAPEUTICS INC?
ESPERION THERAPEUTICS INC (ESPR) operates in the Health Care sector and the Pharmaceuticals industry.